Ipsen | Income Statement

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,225
1,275
1,444
1,585
1,909
2,225
Cost of Goods Sold (COGS) incl. D&A
306
310
337
353
386
454
Gross Income
919
965
1,107
1,231
1,523
1,771
SG&A Expense
743
762
858
976
1,123
1,255
EBIT
-
203
-
255
401
515
Unusual Expense
15
30
71
45
4
37
Non Operating Income/Expense
50
35
60
62
18
21
Interest Expense
2
3
1
5
9
8
Pretax Income
202
206
236
269
371
494
Income Tax
59
54
48
44
101
108
Equity in Affiliates
-
2
3
2
1
1
Consolidated Net Income
142
155
190
226
271
387
Net Income
142
154
189
226
270
388
Net Income After Extraordinaries
131
155
189
226
268
386
Net Income Available to Common
153
154
190
226
272
390
EPS (Basic)
1.84
1.87
2.31
2.74
3.30
4.70
Basic Shares Outstanding
83
82
82
82
83
83
EPS (Diluted)
1.83
1.87
2.30
2.73
3.28
4.68
Diluted Shares Outstanding
83
82
83
83
83
83
EBITDA
202
247
296
304
499
642
Other Operating Expense
16
-
-
-
-
-
Non-Operating Interest Income
-
8
2
1
1
3
Minority Interest Expense
1
1
1
1
1
1

About Ipsen

View Profile
Address
65, quai Georges Gorse
Boulogne-Billancourt Ile-de-France 92650
France
Employees -
Website http://www.ipsen.com
Updated 07/08/2019
Ipsen SA manufactures pharmaceutical products for oncology, neuroscience and rare diseases. It operates through following segments: Specialty Care and Consumer Healthcare. The Specialty Care segment focuses on Oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and Rare Diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin.